Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
Hope S RugoGerardo A UmanzorFrancisco J BarriosRosa H VasalloMarco A ChivalanSuyapa BejaranoJulio R RamírezLuis FeinRuben D KowalyszynE Douglas KramerHui WangMin-Fun R KwanDavid L Cutlernull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
oPac + E increased the confirmed tumor response versus IVpac, with trends in PFS and OS. Neuropathy was less frequent and severe with oPac + E; neutropenic serious infections were increased. Elevated liver enzymes at baseline predispose oPac + E patients to early neutropenia and serious infections (funded by Athenex, Inc; ClinicalTrials.gov identifier: NCT02594371).